Neuralify raises $22M Series B to expand AI EEG into ambulatory epilepsy monitoring
Summary
Paris-based Neuralify secured €22M Series B from Cathay Innovation and new investor Elaia Partners to expand their AI EEG platform into ambulatory long-term monitoring for epilepsy presurgical evaluation. Current hospital-based EEG monitoring requires 5-14 day inpatient admission — Neuralify's home ambulatory EEG AI would reduce this to outpatient monitoring with equivalent diagnostic accuracy.
Why it matters
Replacing 14-day inpatient EEG monitoring with outpatient ambulatory monitoring would save approximately $15,000-50,000 per patient in hospital costs while simultaneously improving patient quality of life during monitoring. The cost-saving narrative makes Neuralify's value proposition compelling to hospital procurement committees.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial